Logo image of PHGE

BIOMX INC (PHGE) Stock Fundamental Analysis

NYSEARCA:PHGE - NYSE Arca - US09090D3017 - Common Stock - Currency: USD

0.5459  +0.01 (+1.15%)

Premarket: 0.551 +0.01 (+0.93%)

Fundamental Rating

2

Overall PHGE gets a fundamental rating of 2 out of 10. We evaluated PHGE against 568 industry peers in the Biotechnology industry. The financial health of PHGE is average, but there are quite some concerns on its profitability. PHGE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PHGE has reported negative net income.
In the past year PHGE has reported a negative cash flow from operations.
In the past 5 years PHGE always reported negative net income.
In the past 5 years PHGE always reported negative operating cash flow.
PHGE Yearly Net Income VS EBIT VS OCF VS FCFPHGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

PHGE has a Return On Assets (-41.00%) which is in line with its industry peers.
PHGE's Return On Equity of -73.41% is in line compared to the rest of the industry. PHGE outperforms 55.11% of its industry peers.
Industry RankSector Rank
ROA -41%
ROE -73.41%
ROIC N/A
ROA(3y)-69.25%
ROA(5y)-59.4%
ROE(3y)-352.46%
ROE(5y)-237.19%
ROIC(3y)N/A
ROIC(5y)N/A
PHGE Yearly ROA, ROE, ROICPHGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PHGE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHGE Yearly Profit, Operating, Gross MarginsPHGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

PHGE has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, PHGE has more shares outstanding
PHGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PHGE Yearly Shares OutstandingPHGE Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PHGE Yearly Total Debt VS Total AssetsPHGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

PHGE has an Altman-Z score of -7.86. This is a bad value and indicates that PHGE is not financially healthy and even has some risk of bankruptcy.
PHGE has a worse Altman-Z score (-7.86) than 69.19% of its industry peers.
PHGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -7.86
ROIC/WACCN/A
WACCN/A
PHGE Yearly LT Debt VS Equity VS FCFPHGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

PHGE has a Current Ratio of 2.48. This indicates that PHGE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.48, PHGE is doing worse than 70.60% of the companies in the same industry.
A Quick Ratio of 2.48 indicates that PHGE has no problem at all paying its short term obligations.
PHGE has a Quick ratio of 2.48. This is in the lower half of the industry: PHGE underperforms 69.01% of its industry peers.
Industry RankSector Rank
Current Ratio 2.48
Quick Ratio 2.48
PHGE Yearly Current Assets VS Current LiabilitesPHGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

1

3. Growth

3.1 Past

PHGE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.62%, which is quite impressive.
EPS 1Y (TTM)43.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PHGE will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.85% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y50.83%
EPS Next 2Y30.6%
EPS Next 3Y18.89%
EPS Next 5Y9.85%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PHGE Yearly Revenue VS EstimatesPHGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2028 2029 2030 2031 2032 100M 200M 300M
PHGE Yearly EPS VS EstimatesPHGE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PHGE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PHGE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHGE Price Earnings VS Forward Price EarningsPHGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PHGE Per share dataPHGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4

4.3 Compensation for Growth

PHGE's earnings are expected to grow with 18.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y30.6%
EPS Next 3Y18.89%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PHGE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOMX INC

NYSEARCA:PHGE (4/21/2025, 8:04:01 PM)

Premarket: 0.551 +0.01 (+0.93%)

0.5459

+0.01 (+1.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-25 2025-03-25/bmo
Earnings (Next)05-19 2025-05-19/bmo
Inst Owners46.75%
Inst Owner Change0%
Ins Owners0.62%
Ins Owner Change9.12%
Market Cap13.63M
Analysts82.5
Price Target7.14 (1207.93%)
Short Float %0.17%
Short Ratio0.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-620%
EPS NQ rev (3m)-620%
EPS NY rev (1m)39.29%
EPS NY rev (3m)41.15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 1.13
EV/EBITDA N/A
EPS(TTM)-5.3
EYN/A
EPS(NY)-1.56
Fwd EYN/A
FCF(TTM)-1.48
FCFYN/A
OCF(TTM)-1.48
OCFYN/A
SpS0
BVpS0.97
TBVpS0.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -41%
ROE -73.41%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.25%
ROA(5y)-59.4%
ROE(3y)-352.46%
ROE(5y)-237.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.66%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.48
Quick Ratio 2.48
Altman-Z -7.86
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)3.92%
Cap/Depr(5y)40.26%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-33.75%
EPS Next Y50.83%
EPS Next 2Y30.6%
EPS Next 3Y18.89%
EPS Next 5Y9.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-43.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-14.99%
EBIT Next 3Y-16.87%
EBIT Next 5Y-13.64%
FCF growth 1Y-73.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-73.72%
OCF growth 3YN/A
OCF growth 5YN/A